KPV is a synthetic tripeptide corresponding to the C-terminal three residues (lysine-proline-valine, positions 11-13) of α-melanocyte-stimulating hormone. Despite its minimal size, KPV retains the anti-inflammatory and antimicrobial activity of full-length α-MSH while lacking the melanocortin-receptor pigmentation and central activity. The compound has been extensively studied in gastrointestinal inflammation research, particularly inflammatory bowel disease preclinical models, and in dermatological inflammation research.
KPV's anti-inflammatory activity operates through nuclear translocation: the tripeptide enters cells via PEPT1 and PEPT2 oligopeptide transporters and reaches the nucleus where it inhibits NF-κB signalling — the master transcription factor for pro-inflammatory cytokine programmes. The downstream effect is suppression of TNF-α, IL-1β, IL-6 and chemokine production from activated immune cells.
Unlike the parent α-MSH or other MSH fragments, KPV does not engage melanocortin receptors at meaningful concentrations — its activity is intracellular and receptor-independent. This explains why it lacks the pigmentation, cardiovascular and central-nervous-system effects of the larger α-MSH analogues.
In the gut, KPV's intestinal absorption via PEPT1 (the principal oligopeptide transporter of the small intestine) makes it one of the few peptides retaining bioactivity after oral administration — the basis for the IBD research interest. Topical KPV research targets dermal inflammation through similar intracellular NF-κB suppression in resident immune cells.
KPV has been the subject of an active IBD preclinical research programme since the early 2000s, with foundational work by Kannengiesser, Becker and colleagues at the University of Erlangen. Published rodent colitis models (DSS-induced, TNBS-induced) consistently document attenuation of inflammation markers, reduced cytokine production, and preserved mucosal architecture with KPV dosing.
The oral bioavailability via PEPT1 — the same transporter that absorbs di- and tripeptides from dietary protein — distinguishes KPV from most peptide compounds and underpins the translational interest in IBD where oral or rectal delivery is essential.
Topical KPV research has documented anti-inflammatory activity in dermal inflammation models including contact dermatitis and atopic dermatitis preclinical assays. The compound is studied for its ability to suppress local cytokine production without the systemic effects of corticosteroids or full-length α-MSH analogues.
Wound healing research has examined KPV both alone and in stack formulations (notably the KLOW Blend of TB-500 + BPC-157 + GHK-Cu + KPV), where the four-compound combination targets four mechanistically distinct repair pathways in parallel.